Can-Fite BioPharma American Depositary Shares
CANF
6 hedge funds and large institutions have $1.3M invested in Can-Fite BioPharma American Depositary Shares in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.01% less ownership
Funds ownership: 0.5% → 0.49% (-0.01%)
12% less capital inflows, than outflows
Capital inflows: $265K | Capital outflows: $302K
14% less funds holding
Funds holding: 7 → 6 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$217K |
| 2 |
Meitav Investment House
Bene-Beraq,
Israel
|
+$48.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Taylor Asset Management
Toronto,
Ontario, Canada
|
-$300K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2K |
CANF Hedge Fund Activity: Q1 2019 in Review
6 of the 4,634 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q1 2019, worth a combined $1.3M — down 29% from $1.84M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of CANF and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was Morgan Stanley, adding an estimated $217K. The largest seller was Taylor Asset Management, cutting an estimated $300K.
- 6 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q1 2019, down from 7 in Q4 2018.
- Funds reported $1.3M of Can-Fite BioPharma American Depositary Shares stock for Q1 2019, down 29% quarter-over-quarter.
- 0 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q1 2019 and 1 closed out, a net change of -1 holder.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q1 2019 was Morgan Stanley, an estimated $217K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q1 2019 was Taylor Asset Management, an estimated $300K sold.
Based on aggregated 13F filings for Q1 2019.